STAT3 and hepatocellular carcinoma: Sorafenib could downregulate p-Stat3 in a dose- and time-dependent manner in HCC cells, while p-Stat3 activation was discovered to be the cause of recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance.